Seval Ay

Publication Activity (10 Years)

Years Active: 2020-2022
Publications (10 Years): 7

Top Venues

Journal of chemotherapy (Florence, Italy)

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Future oncology (London, England)

European journal of breast health

İstanbul Medeniyet Üniversitesi Tip Fakültesi

This page only lists publications with an associated author ORCID identifier.

Affiliation History

İstanbul Medeniyet Üniversitesi Tip Fakültesi

Turkey

MD, fellow :: medikal onkoloji

Publications

Ozgecan Dulgar, Bala Başak Öven, Muhammet Mustafa Atcı, Rukiye Arıkan, Seval Ay, Murat Ayhan, Oğuzhan Selvi, Deniz Tataroğlu Özyükseler, Ertuğrul Bayram, Erkan Özcan, Ayse Irem Yasin, Mahmut Gümüş
Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy? Expert review of anticancer therapy 22 (7) (2022)
Seval Ay, Muhammet Mustafa Atcı, Rukiye Arıkan, Ozgecan Dulgar, Deniz Tataroğlu Özyükseler, Nail Paksoy, Izzet Dogan, Buğra Öztosun, Didem Taştekin, Bala Başak Öven, Mahmut Gümüş
FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer. Journal of chemotherapy (Florence, Italy) 34 (7) (2022)
Muhammet Mustafa Atcı, Baran Akagunduz, Metin Demir, Rukiye Arıkan, Seval Ay, Muhammet Ozer, Murat Ayhan, Ibrahim Cil, Nazan Demir, Nilay Sengul Samanci, Gökhan Karakaya, Gokcen Tugba Cevik, Arif Hakan Onder, Oguzhan Selvi, Abdullah Sakin
The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study. Journal of chemotherapy (Florence, Italy) (2022)
Atakan Topcu, Muhammet Mustafa Atcı, Saban Secmeler, Mehmet Besiroglu, Murat Ayhan, Metin Ozkan, Oktay Bozkurt, Zuhat Urakci, Seval Ay, Caglayan Geredeli, Ayse Irem Yasin, Haci Mehmet Turk
Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer. Future oncology (London, England) 17 (31) (2021)
Muhammet Mustafa Atcı, Caglayan Geredeli, Seval Ay, Abdullah Sakin, Biray Ertürk, Şaban Seçmeler, Serdar Arıcı, Ruhper Çekin, Nurgül Yaşar, Orçun Can, Sener Cihan, Mahmut Gümüş
Clinical and Pathological Characteristics of Patients with High-Risk Breast Cancer Based on BRCA Mutation Profiles: A Retrospective Study. European journal of breast health 17 (2) (2021)
Deniz Tataroğlu Özyükseler, Mustafa Basak, Seval Ay, Aygül Koseoglu, Serdar Arıcı, Abdilkerim Oyman, Heves Sürmeli, Merve Turan, Nedim Turan, Hatice Odabaş, Mahmut E Yıldırım
Prognostic factors of ado-trastuzumab emtansine treatment in patients with metastatic HER-2 positive breast cancer. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 27 (3) (2020)
Ozgecan Dulgar, Deniz Tataroğlu Özyükseler, Mustafa Başak, Seval Ay, Deniz Tural, Mahmut Emre Yıldırım, Mahmut Gümüş
Is the duration of castration resistance predictive for sequential treatment responses in the metastatic castration-resistant prostate cancer setting? Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 27 (6) (2020)

Seval Ay.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Seval Ay